Schering-Plough Says Organon Deal Offers Key To Women’s Health Market
Executive Summary
Schering-Plough is looking to build a presence in the women's health care market with the integration of Organon Biosciences
You may also be interested in...
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates
Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors